Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019
Xenon to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
April 30, 2019
Xenon's Annual Meeting of Shareholders will be held on June 3, 2019. View Notice of Meeting and supporting materials.
April 29, 2019
Xenon to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
April 24, 2019
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
February 26, 2019
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
